Events & Presentations
hVIVO FY25 Results: Growth, Acquisitions and What Comes Next in 2026
Upcoming Events
SaxoCell Conference on Cell and Gene Therapy
Explore the Future of Cell and Gene Therapy Development hVIVO will be attending the SaxoCell Conference, a focused ...
Capital Markets Day 2026
The event will provide investors with a deeper understanding of hVIVO's strategic evolution from specialist human ...
11th German Pharm-Tox Summit 2026
The GPTS is organized by the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT). The ...
PSI 2026
Join us at the PSI 2026 Conference, taking place 15–17 June at the award‑winning ICC Belfast. This year’s event brings ...
PCMG26
PCMG26 is a leading annual gathering for professionals in pharmaceutical clinical outsourcing, vendor management, and ...
BIO International Convention
hVIVO is proud to be attending BIO International Convention 2026, the world’s largest gathering of biotechnology, ...
American Society for Virology
The American Society for Virology (ASV) is a premier scientific organisation dedicated to advancing the understanding ...
Options XIII
Options XIII is a major global conference dedicated to advancing influenza science, policy, and pandemic preparedness, ...
ERS Congress
The ERS International Congress is one of the world’s leading events in respiratory medicine, bringing together ...
28th Annual Conference of the European Society for Clinical Virology
The 28th Annual Conference of the European Society for Clinical Virology brings together leading experts in virology, ...
EASD 2026
The EASD 2026 Annual Meeting is one of the world’s leading forums for diabetes research and clinical innovation, ...
CPHI 2026
CPHI 2026 is one of the world’s largest and most influential events for the pharmaceutical supply chain, bringing ...
Past Presentations
Past Presentations
Capital Markets Day 2026
View the presentations given at our Capital Markets Day 2026.
Trading Update FY25
HVIVO plc (HVO:AIM) reported an unaudited FY25 trading update highlighting resilient company performance amid a challenging macro backdrop, with revenue of £46.7 million in line with revised guidance and a positive low single-digit adjusted EBITDA margin, outperforming market expectations.
HVIVO PLC - Interim Results
Welcome to the HVO PLC interim results investor presentation.
H1 25 Trading Update
hVIVO's first half 2025 trading update, presented by Yamin Khan
Full Year Results 2024
Financial performance was a record year for hVIVO and also a transformational one for operations.